• Achieve outlined a path to potential FDA approval of cytisinicline for smoking cessation, with a PDUFA date of June 20, 2026.
• Commercial launch planning targets Q4 2026, with continuing launch activity projected into 1H 2027.
• Financing totals up to $354 million, including $180 million upfront, with up to $174 million in milestone-driven warrants tied to FDA approval.
• Phase 3 pooled data showed continuous abstinence of 31.5% vs 8.2% at weeks 9-12; odds ratio 5.3; p<0.0001.
• For vaping cessation, Phase 2 ORCA-V1 reported 31.8% vs 15.1% continuous e-cigarette abstinence at weeks 9-12; odds ratio 2.64; p=0.035.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.